Pregabalin Pharmacology and Its Relevance to Clinical Practice
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary: Pregabalin is a potent ligand for the alpha‐2‐delta subunit of voltage‐gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models. In addition, pregabalin has been shown to be a highly effective adjunctive therapy for partial seizures in clinical trials. Potent binding to the alpha‐2‐delta site reduces depolarization‐induced calcium influx with a consequential modulation in excitatory neurotransmitter release. Pregabalin has no demonstrated effects on GABAergic mechanisms. Pregabalin demonstrates highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. Absorption is extensive, rapid, and proportional to dose. Time to maximal plasma concentration is ∼1 h and steady state is achieved within 24–48 h. These characteristics reflect the observed onset of efficacy as early as day two in clinical trials. High bioavailability, a mean elimination half life (t 1/2) of 6.3 h, and dose‐proportional maximal plasma concentrations and total exposures predict a dose–response relationship in clinical practice and allow an effective starting dose of 150 mg/day in clinical practice without need for titration. Administration with food has no clinically relevant effect on the amount of pregabalin absorbed, providing for a dosing regimen uncomplicated by meals. Pregabalin does not bind to plasma proteins and is excreted virtually unchanged (<2% metabolism) by the kidneys. It is not subject to hepatic metabolism and does not induce or inhibit liver enzymes such as the cytochrome P450 system. Therefore, pregabalin is unlikely to cause, or be subject to, pharmacokinetic drug–drug interactions—an expectation that has been confirmed in clinical pharmacokinetic studies. However, dose adjustment may be necessary in patients with renal insufficiency. Thus, the pharmacological and pharmacokinetic profiles of pregabalin provide a predictable basis for its use in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex
Fink, K., Dooley, D. J., Meder, W. P., Suman-Chauhan, N., Duffy, S., Clusmann, H., & Göthert, M. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00172-1 · Cited by 496
Lauria-Horner, B. A., & Pohl, R. B. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.663 · Cited by 327
Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function
Randinitis, E. J., Posvar, E. L., Alvey, C. W., Sedman, A. J., Cook, J. A., & Bockbrader, H. N. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003251119 · Cited by 257
Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin
Dooley, D. J., Mieske, C. A., & Borosky, S. A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00769-2 · Cited by 226
Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies
Suman-Chauhan, N., Webdale, L., Hill, D. R., & Woodruff, G. N. (1993) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(93)90155-3 · Cited by 225
Dooley, D. J., Donovan, C. M., & Pugsley, T. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39009-3 · Cited by 217
Taylor, C. P., Vartanian, M. G., Yuen, P., Bigge, C. F., Suman‐Chauhan, N., & Hill, D. R. (1993) · Epilepsy Research · doi:10.1016/0920-1211(93)90070-n · Cited by 158
Errante, L. D., & Petroff, O. A. C. (2003) · Seizure · doi:10.1016/s1059-1311(02)00295-9 · Cited by 123
Clinical pharmacokinetics of new antiepileptic drugs
Walker, M. C., & Patsalos, P. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00021-6 · Cited by 114
Pregabalin As Adjunctive Therapy for Partial Seizures
Brodie, M. J. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.455004.x · Cited by 91
Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer’s disease
Thal, L. J., Forrest, M., Loft, H., Mengel, H., & for the Lu25-109 Study Group (2000) · Neurology · doi:10.1212/wnl.54.2.421 · Cited by 55
Pregabalin pharmacokinetics and safety in healthy volunteers Results from two phase 1 studies
Bockbrader, H. N., Hunt, T. L., Strand, J. J., Posvar, E. L., & Sedman, A. J. (2000) · Cited by 36
Pharmacokinetic Considerations in Prescribing Antiepileptic Drugs
Faught, E. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00004.x · Cited by 29
Cited by
Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Leppik, I. E., Tomson, T., & Perucca, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01561.x · Cited by 1,156
The mechanisms of action of gabapentin and pregabalin
SILLS, G. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.003 · Cited by 671
Tiippana, E. M., Hamunen, K., Kontinen, V. K., & Kalso, E. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000261517.27532.80 · Cited by 532
Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update
Patsalos, P. N., Spencer, E. P., & Berry, D. J. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000546 · Cited by 477
Molecular and cellular mechanisms of pharmacoresistance in epilepsy
Remy, S., & Beck, H. (2006) · Brain · doi:10.1093/brain/awh682 · Cited by 406
Metadata
- Authors
- Ben‐Menachem, E.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 45
- Issue
- s6
- Pages
- 13-18
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2076516150
- Cited by
- 542
- References
- 15
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.